No Blys for Vera
Atacicept hits in phase 2, but uncompetitive data are seen as good news for its IgAN rivals.
Key data catalysts for the industry’s small players
Intercept looks for redemption in Nash in the third quarter, while Kymera, Zealand and Anavex hope for share price boosts.
Reata rout leaves next project in doubt
Bardoxolone looks dead after yesterday’s adcom vote, but what about omaveloxolone?
